Holen Sie sich die Stockscreener-App
1.285
3.76%
-0.045
Schlusskurs vom Vortag:
$1.33
Offen:
$1.3
24-Stunden-Volumen:
653.35K
Relative Volume:
0.63
Marktkapitalisierung:
$77.96M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.40M
KGV:
-1.831
EPS:
-0.7018
Netto-Cashflow:
$-18.84M
1W Leistung:
-2.29%
1M Leistung:
-16.88%
6M Leistung:
-26.01%
1J Leistung:
-14.67%
1-Tages-Spanne:
$1.27
$1.34
1-Wochen-Bereich:
$1.27
$1.43
52-Wochen-Spanne:
$0.87
$3.19
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Firmenname
MAIA Biotechnology Inc
Sektor
Branche
Telefon
312 416 8592
Adresse
444 West Lake Street, Suite 1700, Chicago
Compare MAIA vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.285 | 80.69M | 0 | -22.40M | -18.84M | -0.7018 |
VRTX
Vertex Pharmaceuticals Inc
|
433.68 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.51 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.60 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.03 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.76 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
MAIA Biotechnology Inc Aktie (MAIA) Neueste Nachrichten
MAIA Biotechnology Awards Executive Bonuses After Successful Financing - tipranks.com
MAIA Biotechnology (NASDAQ: MAIA) director receives 27,258 stock options at $1.40 - Stock Titan
MAIA Biotechnology (MAIA) awards director 27,907 options at $1.40 - Stock Titan
MAIA (MAIA) director receives grant of 27,258 stock options - Stock Titan
MAIA Biotechnology (MAIA) director granted 33,748 stock options - Stock Titan
MAIA (MAIA) director receives 28,556 stock options at $1.40 strike - Stock Titan
[Form 4] MAIA Biotechnology, Inc. Insider Trading Activity - stocktitan.net
MAIA Biotechnology (MAIA) awards cash bonuses after recent capital raise - Stock Titan
Noble Financial Maintains MAIA Biotechnology(MAIA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Bond Watch: How does MAIA Biotechnology Inc compare to its peersEarnings Recap Report & Growth-Oriented Investment Plans - baoquankhu1.vn
MAIA Highlights Promising Phase 2 NSCLC Survival Outcomes - tipranks.com
Treasury Yields: Is now the right time to enter MAIA Biotechnology Inc2026 Price Momentum & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
MAIA Biotechnology reports >2-year overall survival for 8 NSCLC patients in Phase 2 THIO-101 - TradingView
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer - The Manila Times
Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer - TradingView
Eight MAIA (NYSE: MAIA) NSCLC patients top two-year survival on Phase 2 regimen - Stock Titan
After prior treatment failed, 8 lung cancer patients lived past 2 years - Stock Titan
Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Drops By 26.2% - MarketBeat
MAIA PE Ratio & Valuation, Is MAIA Overvalued - Intellectia AI
MAIA Showcases THIO-101 NSCLC Data at ELCC 2026 - The Globe and Mail
MAIA Biotechnology presents THIO-101 poster showing sustained responses in relapsed NSCLC - TradingView
MAIA Biotechnology (NYSE American: MAIA) presents ELCC 2026 trial poster - Stock Titan
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - finance.yahoo.com
MAIA Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
MAIA Biotechnology, Inc. 2025 Annual 10-K SEC Filing Overview: Private Placements, Warrants, and Equity Transactions - Minichart
MAIA Biotechnology (NYSEAMERICAN:MAIA) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS - marketbeat.com
MAIA Biotechnology 10-K: Operating loss $24.27M, Net loss $22.40M; Cash $8.66M - TradingView
MAIA: Advanced clinical pipeline and $33M capital raise position company for pivotal 2026 milestones - TradingView
MAIA Biotechnology (MAIA) advances ateganosine with Fast Track and Phase 3 NSCLC trial - Stock Titan
Market Review: Will MAIA Biotechnology Inc outperform small cap indexes2026 Market WrapUp & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Fundamentals Check: What are the future prospects of MAIA Biotechnology IncPortfolio Update Report & AI Driven Price Forecasts - baoquankhu1.vn
Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Expands By 17.9% - MarketBeat
MAIA Biotechnology (MAIA) Expected to Announce Quarterly Earnings on Friday - Defense World
MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Up 0.7%Still a Buy? - MarketBeat
MAIA Earnings History & Surprises | EPS & Revenue Results | MAIA BIOTECHNOLOGY INC (NYSEARCA:MAIA) - ChartMill
Is the Market Bullish or Bearish on MAIA Biotechnology Inc? - Sahm
MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock - Sahm
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - GlobeNewswire Inc.
MAIA Biotechnology Completes $30 Million Public Stock Offering - TipRanks
Maia Biotechnology Inc enters underwriting agreement with Konik Capital PartnersSEC filing - marketscreener.com
Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital PartnersSEC Filing - TradingView
MAIA Biotechnology (NYSE American: MAIA) closes $30M common stock raise - Stock Titan
MAIA Biotechnology Prices $30 Million Offering of 20 Million Shares at $1.50 - TradingView
[424B5] MAIA Biotechnology, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
MAIA Shares Fall After Pricing of $30 Million Public Offering - marketscreener.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
MAIA Biotechnology shares drop 29% on discounted stock offering By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's Pre-Market SessionAdial Pharmaceuticals (NASDAQ:ADIL), Ensys - Benzinga
Cancer immunotherapy firm MAIA raises $30M for trials, costs - Stock Titan
MAIA Biotechnology Prices $30 Mln Public Offering Of Shares At $1.50/shr; Stock Down - Nasdaq
MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock - ChartMill
Finanzdaten der MAIA Biotechnology Inc-Aktie (MAIA)
Umsatz
Nettogewinn
Free Cashflow
ENV
MAIA Biotechnology Inc-Aktie (MAIA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| CHAOUKI STEVEN M | Director |
Dec 22 '25 |
Buy |
1.22 |
40,849 |
49,999 |
151,873 |
| Louie Ngar Yee | Director |
Dec 22 '25 |
Buy |
1.22 |
81,699 |
100,000 |
1,248,888 |
| Smith Stan | Director |
Dec 05 '25 |
Buy |
1.20 |
13,740 |
16,441 |
4,580 |
| Vitoc Vlad | Chief Executive Officer |
Nov 28 '25 |
Buy |
1.14 |
50,000 |
56,830 |
881,421 |
| Vitoc Vlad | Chief Executive Officer |
Nov 26 '25 |
Buy |
1.05 |
22,000 |
23,019 |
853,421 |
| Luput Cristian | Director |
Nov 26 '25 |
Buy |
1.08 |
20,000 |
21,616 |
419,483 |
| Luput Cristian | Director |
Nov 28 '25 |
Buy |
1.11 |
18,145 |
20,230 |
437,628 |
| Smith Stan | Director |
Nov 26 '25 |
Buy |
1.04 |
15,000 |
15,582 |
1,364,289 |
| Luput Cristian | Director |
Nov 25 '25 |
Buy |
0.98 |
10,000 |
9,785 |
399,483 |
| Vitoc Vlad | Chief Executive Officer |
Nov 25 '25 |
Buy |
0.97 |
10,500 |
10,144 |
831,421 |
1.90%
1.08%
Kapitalisierung:
|
Volumen (24h):